Message
Meta Text Info
Fetching Project...
Polpharma Santo’s Plant Expansion
Project ID:
1903202601
Project Sector:
Healthcare & Pharmaceuticals
Project Name:
Polpharma Santo’s Plant Expansion
Photo source:
Project Description
The project involves the expansion of the existing Polpharma Santo (JSC “Khimpharm”) pharmaceutical production facility in Shymkent, Republic of Kazakhstan, with the construction of new manufacturing buildings and laboratory spaces. It aims to significantly increase the plant’s capacity to produce 38 types of medicines targeting common and socially important diseases such as oncology, cardiovascular conditions, infectious diseases, chronic illnesses, and tuberculosis, in compliance with international GMP quality standards. The expansion is part of a strategic initiative to boost domestic pharmaceutical production, reduce dependence on imports, and strengthen national drug security, as outlined by government directives. It will also include enhanced R&D capabilities to support scientific research and innovation within the sector. The project is being coordinated through a government‑approved investment agreement between the Ministry of Health of the Republic of Kazakhstan and Khimpharm JSC under the oversight of the Prime Minister’s Office. The development is expected to create approximately 300 new jobs and underpin export growth in the Central Asian region. The initiative reflects broader state policy to attract private investment and build sustainable local pharmaceutical infrastructure.
Project Phase:
Engineering Design & Planning
Start Date:
Value
Investment Value:
75 000 000 $
End Date:
12/31/2029
Location:
Turkistan Region, Kazakhstan
Involved Companies
Company:
░░░░░░░░░░░░░
Role:
░░░░░░░░░░░░░░░░░░░░░░░
Address:
░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Phone:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Email:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Website:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Other links:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Key Contacts
Name:
░░░░░░░░░░░░░
Position:
░░░░░░░░░░░░░░
Phone:
Value
Email:
░░░░░░░░░░░░░░░░░░░░░░░░░░░
Links:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Name:
░░░░░░░░░░░░░░░░
Position:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Phone:
Value
Email:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Links:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Company:
░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Role:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Address:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Phone:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Email:
░░░░░░░░░░░░░░░░░
Website:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Other links:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Key Contacts
Name:
░░░░░░░░░░░░░░░░░░░░░░░░░░
Position:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Phone:
░░░░░░░░░░░░░░
Email:
░░░░░░░░░░░░░░░░░░░░
Links:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Name:
░░░░░░░░░░░░░░░░░░░░░░░░░░
Position:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Phone:
░░░░░░░░░░░░░░
░░░░░░░░░░░░░░░░░░░░
Email:
Links:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Company:
VALUE
Phone:
Value
Email:
Value
Address:
Value
Role:
Value
Website:
Value
Other links:
Value
Key Contacts
Name:
Value
Position:
Value
Phone:
Value
Value
Email:
Links:
Value
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Company:
VALUE
Role:
Value
Address:
Value
Phone:
Value
Email:
Value
Website:
Value
Other links:
Value
Key Contacts
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Company:
VALUE
Role:
Value
Address:
Value
Phone:
Value
Email:
Value
Website:
Value
Other links:
Value
Key Contacts
Name:
Value
Position:
Value
Value
Phone:
Email:
Value
Links:
Value
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Other important details
The expanded facility will comply with international GMP quality standards, enabling future export capabilities beyond Kazakhstan.
The project forms part of broader government efforts to localize pharmaceutical production and improve national healthcare resilience.
Creation of R&D and laboratory capacities supports innovation and quality control, not just manufacturing.
Historical context indicates Polpharma Santo (under Chimpharm brand) has already invested over $130 million in the Shymkent site and produces a wide portfolio of products.
Publication/Revision Date:
3/19/2026